Introduction
Like many apparently new developments prostate brachytherapy was ®rst attempted many years ago; ®rst by Pasteau 3 The technique appeared to offer an effective and convenient alternative to radical prostatectomy but by the late 1980s had been largely abandoned. It is important to analyse the reasons for this failure because there are valuable lessons to be learned when reviewing newly introduced techniques. The main reason for failure was that the manual placement of iodine seeds by the open retropubic technique was dif®-cult to perform so that seed placement was frequently suboptimal and resulted in signi®cant hot spots and cold spots within the prostate gland. The problem was compounded by the fact that the early techniques for determining the distribution and dose of Iodine 125 seeds was relatively crude and did not have the advantage of modern computer algorithms to determine accurately dose distribution. Follow up of patients implanted by the retropubic technique not only showed morbidity as a result of inadvertent hot spots but also recurrences which became more apparent when regular PSA testing became available. There was also a signi®cant contribution to morbidity from the open retropubic surgery required for seed placement. In those cases where a satisfactory implant was achieved the results were good but, because it was so dif®cult to ensure the achievement of satisfactory seed placement, the technique was correctly and understandably abandoned.
New techniques of brachytherapy
In 1981 Holm and Gammelgaard 4 described the technique of transrectal ultrasound with template guidance that allowed accurate positioning of needles within the prostate. This was ®rst developed for guided needle biopsy but it soon became apparent that similar techniques could be used to guide radioactive sources accurately into the prostate and that this could be done percutaneously under ultrasound control. 5 This has formed the basis of new techniques in brachytherapy. This is performed as a two-stage procedure. The ®rst stage is to use transrectal ultrasound to de®ne the prostate volume and use the information from the template co-ordinates to plan the number and position of radioactive sources required to deliver a homogeneous dose of radiation to the prostate. At the second stage the sources are inserted into their pre-planned position in the prostate using a template. Needles are inserted through the perineal skin as a closed procedure.
It is possible to plan the implant from CT data but this tends to over-estimate the volume and can result in more sources being placed near the rectal wall with a consequent increased risk of radiation proctitis.
The total dose of radiation delivered to the prostate and the distribution of dose is determined by a computerised software programme. A variety of different programmes are available depending on the type of isotope and regime of treatment to be used.
There are essentially two forms of brachytherapy which are as follows.
Permanent implants
This is the commonest form of prostate brachytherapy and several thousand patients have been treated to date. For permanent implantation the sources are left within the prostate and deliver their radiation over several weeks or months. Iodine 125 has a half life of 60 d and it is usual to prescribe a minimum peripheral dose of 160 Gy to a volume which includes the prostate capsule plus a 2 or 3 mm margin. This means that 80 Gy is delivered in the ®rst 60 d and the remainder at decreasing dose rates over the next 4 ± 6 months. Palladium 103 has a half life of 17 d which is 3 ± 4 times as fast as that of Iodine 125. Palladium is used by some centres for high Gleason grade tumours which are thought to be proliferating faster than low grade ones. There is as yet, however, little data either on the proliferation rate of human prostate cancer or good evidence of improved ef®cacy. Because of the higher dose rate which is more biologically effective a dose rate correction is made for Palladium 103 so that instead of 160 Gy the minimum peripheral dose is reduced to 115 Gy.
Iodine 125 has an energy of 27±35 KV and Palladium 20 ± 23 KV. The low energy means that there is not much penetration into tissue and this combined with the inverse square law results in the dose falling to less than 50% of the minimum peripheral dose within a few millimetres. This therefore provides a signi®cant advantage in terms of reduction of dose to adjacent critical structures such as the rectum and neurovascular bundles but is equally a limitation in dealing with disease more than 3 or 4 mm outside the prostate capsule.
Successful prostate brachytherapy requires considerable team work and there is a steep learning curve both for implant dosimetry and seed implantation before acceptable dose coverage is achieved in most patients. This is in some way similar to the learning curve for radical prostatectomy which should successively reduce the complications and the risk of pathologically positive resection margins. Both procedures should be done in centres with specialised expertise.
The main advantage of permanent implantation is that the treatment is completed in a single application which can often be done as an out-patient procedure or with a single overnight stay in hospital. The disadvantage is the need to handle live radioactive sources. The radiation energy of the sources, however, is so low that exposure to other persons is negligible with straightforward radiation protection procedures.
Removable implants
Source carrying needles or tubes are placed in the prostate and can be afterloaded with a radioactive source that is then removed on completion of treatment. There are two potential ways of delivering treatment.
Continuous Low Dose Rate (LDR)
The source carriers are loaded with low activity iridium wire which delivers a continuous low dose rate for the duration of the implant.
High Dose Rate Implants (HDR)
With high dose rate treatments a high activity source is used to deliver a pulse of radiation to the prostate. Because larger doses of radiation given at a high dose rate are poorly tolerated it is necessary to fractionate treatment with HDR techniques and it is common to deliver 4±6 fractions of treatment either separated over the space of 2 or 3 d or done in two separate applications. With modern afterloading techniques radiation exposure is not a problem but because source tubes have to remain within the prostate for the duration of the implantation and exit through the perineum they cannot be tolerated for more than a day or two and it is usually necessary with these techniques to give most of the treatment with fractionated external beam radiation and to use brachytherapy as a localised boost to the prostate. This signi®cantly increases both the duration and cost of the treatment.
Indications for and contra-indications to brachytherapy
For Iodine 125 and Paladium 103 permanent seed implants the selection criteria are similar to selection for radical prostatectomy. Patients who are deemed un®t for prostatectomy may, however, be suitable for brachytherapy. Selection criteria are broadly as follows:
life expectancy greater than 10 y histologically con®rmed adenocarcinoma of prostate disease con®ned within the prostate capsule, namely, T1±T2C as con®rmed by transrectal ultrasound and/or endorectal MRI scanning no evidence of metastatic disease no TURP prostate volume less than 50 cc (for larger prostates hormonal manipulation with LHRH analogues AE androgen blockers for three months will reduce the prostate volume to less than 50 cc). PSA less than 50. The cut off level of 50 is higher than usually accepted for surgery and will almost certainly include a proportion of patients whose disease has extended through the prostate capsule or distantly even though diagnostic imaging tests are normal. Results, however, show that a 5 y PSA relapse free survival of 30±40% can still be achieved in such patients and it may be reasonable because of the low morbidity of the procedure to accept patients for brachytherapy rather than external beam radiation. This is, however, still an area of controversy.
Staging biopsies may be performed under ultrasound control where there is a high risk of extra-capsular involvement as predicted by PSA, Gleason grade and stage. Where extra-capsular spread is con®rmed external beam radiotherapy and/or a rigid needle afterloading implant is recommended.
For permanent seed implants which deliver a very high dose of radiation to the urethra patients who have had a previous TURP should be excluded because there is a high risk of developing incontinence in this group of patients. The same is not, however, such a problem with patients treated using other techniques where the central dose is less.
For removable implants using rigid source carriers it is possible to extend the indications to T3 carcinomas because the sources can be held in position outside the prostate capsule. This is dif®cult to achieve with seed implants which are thus con®ned to T1 and T2 cases.
Results of brachytherapy
When evaluating results of any treatment for prostate cancer it is important to have adequate information on the distribution of prognostic factors within the population treated and for results to include information on survival, local control, incidence of metastases and PSA relapse free survival.
The largest body of mature data is from centres who have treated T1 and T2 tumours with iodine seed implantation and these are summarised in Table 1 .
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These series show encouraging results in terms of the number of patients who remain clinically disease free at follow up of up to 5 y. PSA control at 2±5 y for the different series ranges from 76±98%. In all these series it is clear that pre-treatment factors, notably baseline PSA, Gleason grade and clinical stage, are strong predictors of subsequent outcome, as would be expected.
For higher risk localised prostate cancer, for example, Gleason grade greater than or equal to 7 and/or high initial PSA, some centres combine external beam radiation with radioactive seed implant. One series has reported on 73 high risk patients treated with external beam radiotherapy and a Pd103 boost. These patients had three year freedom from biochemical failure of 79% at 3 y and, where the PSA was initially less than 15 ng/ml, 87% were biochemically free of disease. 13 At the Northwest Hospital in Seattle 232 patients have been treated by combining external beam radiotherapy with a permanent radioactive seed implant between 1986 and 1994. At 5 y 79% of patients showed freedom from biochemical failure with a disease free survival of 80%. 10 With regard to removable implants the published series contains small groups of patients ranging from 21±36.
14±16 These small series have combined high dose rate prostate brachytherapy with external beam radiotherapy. Local control after short follow up periods ranged from 76 ±92%.
Complications
Patients commonly experience obstructive and irritative urinary symptoms following prostate brachytherapy. Late complications appear to be low and the experience of Beyer and Priestly 12 and Blasko et al 17 is that between 4 and 8% of patients require minor surgical procedures such as catheterisation or cystoscopy in the post operation period. Proctitis occurs in less than 2% of patients receiving seed implant as the sole treatment. Incontinence occurred in 0±1% of patients in these series when no previous TURP had been performed.
Where TURP has been performed the incontinence rate is up to 50%. However, there has been a recent report of 19 patients having had previous TURP, only one of whom developed stress incontinence following seed implant. 18 This low rate of incontinence was attributed to distributing the radioactive seeds at some distance from the urethra. Early series 7, 8 reported maintenance of potency in 81% and 75% of previously potent patients after 2±3 y respectively. Blasko et al 17 reported that 85% of under 70s and 50% of over 70s remained potent 3 y after prostate brachytherapy.
Advantages of radioactive iodine seed brachytherapy over surgery and external beam radiotherapy
Convenience
Patients having single modality iodine seed implantation can often have this as an out patient procedure or with a single overnight stay in hospital. The majority are back at work or have resumed normal activity within a week of their implant.
Cost
The relative costs of the three procedures depend on the health care system in which they are delivered. The best data comes from American Health Insurance providers. 19 These have shown that iodine seed implants are 25% cheaper than external beam radiotherapy and 50% cheaper than radical surgery. These costings only include the direct costs and do not include the added indirect costs to the patients which may be related to the costs of attending for daily radiotherapy and those related to prolonged periods away from work.
Low morbidity
The low incidence of incontinence, rectal complications and high preservation of potency compare well with surgical and external beam radiotherapy series.
Applicability
Brachytherapy can be used in patients who are not ®t for radical surgery and can also be used for patients who are not suitable for radical external beam radiation because of problems relating to the presence of bowel within the radiation ®elds, particularly in patients with in¯ammatory bowel disease.
Effectiveness
In terms of PSA freedom from progression, prostate brachytherapy results appear equivalent to those of radical prostatectomy when strati®ed by initial PSA. 20, 21 Freedom from PSA progression appears inferior for patients treated with external beam radiotherapy compared to prostate brachytherapy. However these series did include patients with T3 prostate cancer.
22,23
Can the results of treatment with different techniques be reasonably compared?
There are unfortunately no large randomised trials comparing different treatments for localised prostate cancer or treatment v a watch and wait policy. There are, however, many observational studies of different treatments but care is needed when analysing these in view of possible confounding factors that will affect outcome. When comparing results of treatment the same outcome indices should be used and should include overall survival, local recurrence rates, metastasis rate, PSA relapse free survival, complications, morbidity and patient derived quality of life data.
Conclusions
Where it has been possible to control for confounding factors brachytherapy appears to perform at least as well as either surgery or external beam radiotherapy. Because of its side effect pro®le, convenience and cost, brachytherapy should therefore be made available as an option for patients with localised carcinoma of the prostate where local treatment is deemed appropriate.
